Overcoming Therapeutic Inertia in Type 2 Diabetes Care-Timing, Context, and Appropriateness of Treatment Intensification

JAMA Netw Open. 2021 Oct 1;4(10):e2130926. doi: 10.1001/jamanetworkopen.2021.30926.

Authors

Rozalina G McCoy^{1

2}, Patrick J O'Connor³

Affiliations

¹ Division of Community Internal Medicine, Department of Medicine, Mayo Clinic, Rochester, Minnesota.
² Division of Health Care Delivery Research, Mayo Clinic Robert D. and Patricia E. Kern Center for the Science of Health Care Delivery, Rochester, Minnesota.
³ HealthPartners Institute, Minneapolis, Minnesota.

No abstract available

Publication types

Comment

MeSH terms

Diabetes Mellitus, Type 2* / drug therapy
Glycated Hemoglobin / analysis
Humans
Hypoglycemic Agents / therapeutic use

Substances

Glycated Hemoglobin A
Hypoglycemic Agents

Grants and funding

K23 DK114497/DK/NIDDK NIH HHS/United States